SOD1 and amyotrophic lateral sclerosis: Using the G93A SOD1 mouse model of ALS, we have previously demonstrated [45] that a single systemic iv administration of MNC hUCB cells, at the low dose of 106 cells, delayed disease progression by at least 2–3 weeks and modestly increased lifespan.